These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
311 related articles for article (PubMed ID: 29463898)
21. Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy. Goleva E; Lyubchenko T; Kraehenbuehl L; Lacouture ME; Leung DYM; Kern JA Ann Allergy Asthma Immunol; 2021 Jun; 126(6):630-638. PubMed ID: 33716146 [TBL] [Abstract][Full Text] [Related]
22. Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis. Kumar P; Saini S; Prabhakar BS Semin Cancer Biol; 2020 Aug; 64():29-35. PubMed ID: 30716481 [TBL] [Abstract][Full Text] [Related]
23. Cancer immunotherapy-related adverse events: causes and challenges. Blidner AG; Choi J; Cooksley T; Dougan M; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Rapoport BL; Anderson R Support Care Cancer; 2020 Dec; 28(12):6111-6117. PubMed ID: 32857220 [TBL] [Abstract][Full Text] [Related]
24. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab. Muto Y; Kitano S; Tsutsumida A; Namikawa K; Takahashi A; Nakamura Y; Yamanaka T; Yamamoto N; Yamazaki N J Dermatol; 2019 Jun; 46(6):498-506. PubMed ID: 30945333 [TBL] [Abstract][Full Text] [Related]
25. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. Bertrand A; Kostine M; Barnetche T; Truchetet ME; Schaeverbeke T BMC Med; 2015 Sep; 13():211. PubMed ID: 26337719 [TBL] [Abstract][Full Text] [Related]
26. Impact of COVID-19 on patients with rheumatic complications of cancer immunotherapy: results of a registry survey. Ghosh N; Tirpack A; Chan KK; Bass AR J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33067320 [TBL] [Abstract][Full Text] [Related]
28. Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment. Di Dalmazi G; Ippolito S; Lupi I; Caturegli P Expert Rev Endocrinol Metab; 2019 Nov; 14(6):381-398. PubMed ID: 31842671 [No Abstract] [Full Text] [Related]
29. Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer. Schofield DJ; Percival-Alwyn J; Rytelewski M; Hood J; Rothstein R; Wetzel L; McGlinchey K; Adjei G; Watkins A; Machiesky L; Chen W; Andrews J; Groves M; Morrow M; Stewart RA; Leinster A; Wilkinson RW; Hammond SA; Luheshi N; Dobson C; Oberst M MAbs; 2021; 13(1):1857100. PubMed ID: 33397194 [TBL] [Abstract][Full Text] [Related]
30. Post-immunotherapy CTLA-4 Ig treatment improves antitumor efficacy. Mok S; Ağaç Çobanoğlu D; Liu H; Mancuso JJ; Allison JP Proc Natl Acad Sci U S A; 2024 Jul; 121(27):e2404661121. PubMed ID: 38923991 [TBL] [Abstract][Full Text] [Related]
31. An anti-CTLA-4 heavy chain-only antibody with enhanced T Gan X; Shan Q; Li H; Janssens R; Shen Y; He Y; Chen F; van Haperen R; Drabek D; Li J; Zhang Y; Zhao J; Qin B; Jheng MJ; Chen V; Wang J; Rong Y; Grosveld F Proc Natl Acad Sci U S A; 2022 Aug; 119(32):e2200879119. PubMed ID: 35925889 [TBL] [Abstract][Full Text] [Related]
32. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Duraiswamy J; Kaluza KM; Freeman GJ; Coukos G Cancer Res; 2013 Jun; 73(12):3591-603. PubMed ID: 23633484 [TBL] [Abstract][Full Text] [Related]
33. T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment. Santegoets SJ; Stam AG; Lougheed SM; Gall H; Scholten PE; Reijm M; Jooss K; Sacks N; Hege K; Lowy I; Cuillerot JM; von Blomberg BM; Scheper RJ; van den Eertwegh AJ; Gerritsen WR; de Gruijl TD Cancer Immunol Immunother; 2013 Feb; 62(2):245-56. PubMed ID: 22878899 [TBL] [Abstract][Full Text] [Related]
34. Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer. van Hooren L; Sandin LC; Moskalev I; Ellmark P; Dimberg A; Black P; Tötterman TH; Mangsbo SM Eur J Immunol; 2017 Feb; 47(2):385-393. PubMed ID: 27873300 [TBL] [Abstract][Full Text] [Related]
35. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. Holmgaard RB; Zamarin D; Munn DH; Wolchok JD; Allison JP J Exp Med; 2013 Jul; 210(7):1389-402. PubMed ID: 23752227 [TBL] [Abstract][Full Text] [Related]
36. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840 [TBL] [Abstract][Full Text] [Related]
37. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes. Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813 [TBL] [Abstract][Full Text] [Related]
39. CTLA-4 antibody-drug conjugate reveals autologous destruction of B-lymphocytes associated with regulatory T cell impairment. Muthana MM; Du X; Liu M; Wang X; Wu W; Ai C; Su L; Zheng P; Liu Y Elife; 2023 Dec; 12():. PubMed ID: 38127423 [TBL] [Abstract][Full Text] [Related]
40. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]